Addyi® (flibanserin) becomes the newest product in Searchlight's industry-leading portfolio focused on women's health, and further builds out the company's commitment to improving female sexual health, alongside its Mona Lisa® IUD portfolio and its combined oral contraceptive (COC) candidate Nextstellis®, which is under review at Health Canada.